Peter Zahradka – författare

Considering the current interest in cellular regulation and intracellular signalling systems, it is surprising that the contribution of ADP-ribosylation reactions to the modulation of a variety of specific cell processes, in parallel with other post-translational modifications such as phosphorylation, has not been generally recognized. While it is not feasible to cover all aspects of ADP-ribosylation, the thirty-one articles contained in this volume provide an overview of recent progress in the field within the context of cell control mechanisms. For the convenience of the reader, the various topics have been grouped into several sections: (a) poly(ADP-ribosyl)ation; (b) mono-ADP-ribosylation; (c) toxin mono-ADP-ribosylation; (d) inhibitors and activators; (e) protein modification with ADP-ribose and its analogues; and (f) non-modification forms of ADP-ribose. The contents of the individual chapters reflect the ideas of the contributors, many of whom have spent their careers attempting to resolve the biological functions of ADP-ribosylation.

The relationship between angiotensin II and hypertension was established in 1898 when angiotensin II was shown to modulate systemic blood pressure. Over the intervening decades, a complete characterization of the renin-angiotensin system (RAS) has been achieved, and our understanding of its biochemistry and physiology has led to the directed development of agents such as ACE inhibitors and receptor antagonists capable of controlling hypertension. More recently, it was shown that angiotensin II is secreted within certain tissues, and that these tissue-specific systems operate independently of the systemic RAS. The novel concept that angiotensin II regulates a number of cardiovascular processes that are unrelated to blood pressure has renewed the interest of both basic and clinical scientists in angiotensin II. The association between angiotensin II and cardiac growth, in particular, has indicated that therapies in use for hypertension may have direct application to the treatment of heart failure. This book focuses on developments in the molecular biology, cellular physiology and structure-function relationships of angiotensin II and its receptors.In addition, this volume covers the therapeutic uses for angiotensin receptor antagonists and considers their potential future applications. This volume aims to be a valuable resource for scientists, practising clinicians and students who are attempting to extend their knowledge in the field of hypertension and heart failure, and who are devoted to improving cardiovascular health.

Thistext, as the tide states, is acompilationofpapersdevoted to the studyofath- erosclerosis,hypertensionanddiabetes.Thesethree distinctdisease entities,although not entirely unrelated, are three ofthe most important disease conditions in the world today.As such, this volumeofresearch papers isofobvious medical impor- tance.Thejustificationofthe energy,time and financial resources directed towards the studyofeachofthese three diseases requiressome discussion. The majority of papers amongst the three diseases that are discussed in this volume are dedicated to the studyofatherosclerosis.This is not by accident.Car- diovasculardisease isthenumberonekillertodayintheworld. IntheUnitedStates almost61 millionAmericanshaveoneormoreformsofcardiovasculardisease.These diseases claimed nearly 1million lives in 1998 alone.Although approximately 80% ofthosewho dieofcardiovasculardisease are 65 yearsofageorolder,asignificant numberofpeople are killed by cardiovascular disease below the ageof65.Ather- osclerotic heart disease in the eoronary vaseulature eausedapproximately~ million deaths in the United States in 1998.At least 12,400,000people are alive todayin the United States with a historyofmyocardial infarctions or ehest pain or both.Clearly,atherosclerotie disease inthe heart isamajormedicalproblem.This disease affeetsbothmenandwomen.Althoughmen are more likelyto experienee aheart attaekand are atgreater risk for eardiovaseular disease,more then ~ofthe people alive today with a historyofheart attacks or angina are females. As weIl,women whodo havemyoeardialinfarctionsare twice aslikely to diefromtheeventwithin afew weeks.Atheroscleroticvasculardisease isnotlimitedtojustthe heart.Anath- erosclerotic ischemic event is the primary causeofstroke today.Although it isnot weIl appreciated, stroke is the number 3 killer inAmerica today and the leading causeofdebilitatingneurological damage.Atherosclerotic vascular disease therefore, has acostintermsofhuman life,qualityoflifeandfinancialburden today thatno otherdisease canmatch.Theseriousnessofthis medicalproblemdemands research attention.

This volume explores all aspects of vascular biochemistry and includes chapters that provide an understanding of vascular function with descriptions of tissue components present in the vascular wall as well as an exploration of the haemodynamic and metabolic activities associated with this function. In addition, some chapters explore the vasculature under conditions which mimic various disease states. The information provided in this volume will provide new insights into the mechanisms that control vascular function as well as therapies designed to treat vascular disease.

Thistext, as the tide states, is acompilationofpapersdevoted to the studyofath- erosclerosis,hypertensionanddiabetes.Thesethree distinctdisease entities,although not entirely unrelated, are three ofthe most important disease conditions in the world today.As such, this volumeofresearch papers isofobvious medical impor- tance.Thejustificationofthe energy,time and financial resources directed towards the studyofeachofthese three diseases requiressome discussion. The majority of papers amongst the three diseases that are discussed in this volume are dedicated to the studyofatherosclerosis.This is not by accident.Car- diovasculardisease isthenumberonekillertodayintheworld. IntheUnitedStates almost61 millionAmericanshaveoneormoreformsofcardiovasculardisease.These diseases claimed nearly 1million lives in 1998 alone.Although approximately 80% ofthosewho dieofcardiovasculardisease are 65 yearsofageorolder,asignificant numberofpeople are killed by cardiovascular disease below the ageof65.Ather- osclerotic heart disease in the eoronary vaseulature eausedapproximately~ million deaths in the United States in 1998.At least 12,400,000people are alive todayin the United States with a historyofmyocardial infarctions or ehest pain or both.Clearly,atherosclerotie disease inthe heart isamajormedicalproblem.This disease affeetsbothmenandwomen.Althoughmen are more likelyto experienee aheart attaekand are atgreater risk for eardiovaseular disease,more then ~ofthe people alive today with a historyofheart attacks or angina are females. As weIl,women whodo havemyoeardialinfarctionsare twice aslikely to diefromtheeventwithin afew weeks.Atheroscleroticvasculardisease isnotlimitedtojustthe heart.Anath- erosclerotic ischemic event is the primary causeofstroke today.Although it isnot weIl appreciated, stroke is the number 3 killer inAmerica today and the leading causeofdebilitatingneurological damage.Atherosclerotic vascular disease therefore, has acostintermsofhuman life,qualityoflifeandfinancialburden today thatno otherdisease canmatch.Theseriousnessofthis medicalproblemdemands research attention.

This volume explores all aspects of vascular biochemistry and includes chapters that provide an understanding of vascular function with descriptions of tissue components present in the vascular wall as well as an exploration of the hemodynamic and metabolic activities associated with this function. In addition, some chapters explore the vasculature under conditions which mimic various disease states. The information provided in this volume will provide new insights into the mechanisms that control vascular function as well as therapies designed to treat vascular disease.

Considering the current interest in cellular regulation and intracellular signalling systems, it is surprising that the contribution of ADP-ribosylation reactions to the modulation of a variety of specific cell processes, in parallel with other post-translational modifications such as phosphorylation, has not been generally recognized. While it is not feasible to cover all aspects of ADP-ribosylation, the thirty-one articles contained in this volume provide a valuable overview of recent progress in the field within the context of cell control mechanisms. For the convenience of the reader, the various topics have been grouped into several sections: (a) poly(ADP-ribosyl)ation; (b) mono-ADP-ribosylation; (c) toxin mono-ADP-ribosylation; (d) inhibitors and activators; (e) protein modification with ADP-ribose and its analogues; and (f) non-modification forms of ADP-ribose. The contents of the individual chapters reflect the ideas of the contributors, many of whom have spent their careers attempting to resolve the biological functions of ADP-ribosylation. We hope that this publication will serve as a useful reference for those investigators that are new to the area as well as those who are actively studying ADP-ribosylation.

The relationship between angiotensin II and hypertension was established in 1898 when angiotensin II was shown to modulate systemic blood pressure. Over the intervening decades, a complete characterization of the renin-angiotensin system (RAS) has been achieved, and our understanding of its biochemistry and physiology has led to the directed development of agents such ·as ACE inhibitors and receptor antagonists capable of controlling hypertension. More recently, it was shown that angiotensin II is secreted within certain tissues and that these tissue-specific systems operate independently of the systemic RAS. The novel concept that angiotensin II regulates a number of cardiovascular processes that are unrelated to blood pressure has renewed the interest of both basic and clinical scientists in angiotensin II. The association between angiotensin II and cardiac growth, in particular, has indicated that therapies currently in use for hypertension may have direct application to the treatment of heart failure. The Manitoba Cardiovascular Forum on Angiotensin Receptor Blockade in Winnipeg was convened October 18-20, 1996 to examine the clinical and basic aspects of angiotensin receptor biology as they apply to hypertension and heart failure. In addition, the potential treatment of these conditions using specific angio­ tensin receptor antagonists was addressed within the context of their immediate therapeutic application and future potential.

Considering the current interest in cellular regulation and intracellular signalling systems, it is surprising that the contribution of ADP-ribosylation reactions to the modulation of a variety of specific cell processes, in parallel with other post-translational modifications such as phosphorylation, has not been generally recognized. While it is not feasible to cover all aspects of ADP-ribosylation, the thirty-one articles contained in this volume provide a valuable overview of recent progress in the field within the context of cell control mechanisms. For the convenience of the reader, the various topics have been grouped into several sections: (a) poly(ADP-ribosyl)ation; (b) mono-ADP-ribosylation; (c) toxin mono-ADP-ribosylation; (d) inhibitors and activators; (e) protein modification with ADP-ribose and its analogues; and (f) non-modification forms of ADP-ribose. The contents of the individual chapters reflect the ideas of the contributors, many of whom have spent their careers attempting to resolve the biological functions of ADP-ribosylation. We hope that this publication will serve as a useful reference for those investigators that are new to the area as well as those who are actively studying ADP-ribosylation.